Pharmacyclics — Technical Presentation (April 2013)
24 slides from Pharmacyclics's technical presentation, Apr 8, 2013
Slide 1: Potent single agent activity of Ibrutinib (PCI-32765) in patients with CLL
Potent single agent activity of Ibrutinib (PCI-32765) in patients with chronic lymphocytic leukemia (CLL): clinical and translational results from an ongoing phase Il study Adrian Wiestner, MD/PhD Hematology Branch, NHLBI, National Institutes of Health Bethesda, MD PLINS » National Heat Sans Lung an
Slide 2: Disclosures: Adrian Wiestner
Disclosures: Adrian Wiestner « Employee of the National Heart, Lung, and Blood Institute. + Supported by the Intramural Research Program, NHLBI, NIH. * Clinical trial of the investigational drug ibrutinib, provided by Pharmacyclics.
Slide 3: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia Accumulation of mature clonal B-cells in CLL: >5,000 clonal B-lymphocytes/uL of blood, CD19+, CD5+, CD23+, CD20 dim, FMC7 negative Small Lymphocytic Lymophoma (SLL): same biology, <5,000 clonal B-lymphocytes/uL of blood
Slide 4: Standard of care: chemoimmunotherapy with fludarabine, cyclophosphamide, rituximab
Standard of care: chemoimmunotherapy with fludarabine, cyclophosphamide, rituximab Less effective for CLLwith deletion of 17p (del 17p). Overall Survival (%) *) on Less tolerable in 204 Hegingle elderly / frail 10} Na upnigietgiag patients. = Sob bh bk oo hm & Time since randomisation (months) Halle
Slide 5: B-cell receptor (BCR) signaling is a key pathogenic pathway in CLL
B-cell receptor (BCR) signaling is a key pathogenic pathway in CLL Antigen GRO @ YZ SZ cpD79 extracellular intracellular Proliferation, Survival, Migration Modified from Wiestner, JCO 2013.
Slide 6: BCR signaling is activated in the lymph node
BCR signaling is activated in the lymph node Activation of SYK kinase Upregulation of BCR downstream of the BCR target genes Blood Bone Lymph Lymph node a“ aH marrow node # 2.5% wi 14.6% x 108 04] = o. of a ; . P va “. a 5 Te wee Te we 2 Herishanu, (...), Wiestner. Blood, 2011
Slide 7: Ibrutinib, an irreversible inhibitor of BTK, disrupts BCR signaling
Ibrutinib, an irreversible inhibitor of BTK, disrupts BCR signaling ~<— EY cD79 nf po extracetitutar intracellular Ibrutinib (PCI-32765) Modified from Wiestner, JCO 2013. aw
Slide 8: Study design
Study design (12-H-0035, Hematology, NHLBI) Ibrutinib 420 mg daily (28 day cycles) Off Treatment: Progressive Disease CLL/SLL up to 86 patients Response Continue . >65y old até Treatment 420 months me ally, 2. del17p Relapsed or treatment naive Blood and lymph node for correlative Off Treatment: Int
Slide 9: Study population
Study population Cohorts * >65,n =24, 8 treatment naive + Del 17p, n= 29, 15 treatment naive At6 months, n = 44 evaluable . Age 33-85 year 58% male 72% Rai stage 3-4 45% bulky disease (>5cm) 74% splenomegaly 12-H-0035, Hematology, NHLBI 9
Slide 10: Safety and tolerability
Safety and tolerability Most common adverse events (grade 1-2): diarrhea, rash, arthralgia, cramps, mouth sores, fatigue. Grade 23 non-hematologic AEs (13% of patients): infection, rash. Hematologic adverse events rare. No drug discontinuation for adverse events. Dose reductions for recurrent grade
Slide 11: Response to ibrutinib at months
Response to ibrutinib at 6 months 17p deletion (n=24) no 17p deletion (n=20) \ \p u PR (IWCLL) & PR (IWCLL) & PR with lymphocytosis & PR with lymphocytosis =PD (n=) §SD (n=1) 12-H-0035, Hematology, NHLBI 11
Slide 12: Transient lymphocytosis on ibrutinib is not indicative of progression
Transient lymphocytosis on ibrutinib is not indicative of progression All patients 300 Mean (+/- sem) } % of pre- 200) treatment ¢ ALC ¢ duringtreatment 1°] @ g .] 0 0 4 2 3004 5 6 At the completion of cycle 12-H-0035, Hematology, NHLBI 12
Slide 13: Change in ALC on ibrutinib
Change in ALC on ibrutinib % change in ALC at 6 months compared to pre-treatment decreased increased 0 = 00 ml ' -25 00 | 00 -50 00 SLL 00 -75 Ec 00 |00 ||| 12-H-0035, Hematology, NHLBI = oy wk a eN -100 13
Slide 14: Lymph node response at months
Lymph node response at 6 months 2 % decrease in SPD of lymph nodes — .5 at 6 months/ pre-treatment 7 -100 a 3 a 12-H-0035, Hematology, NHLBI 14
Slide 15: Volumetric measurement of spleen response at months
Volumetric measurement of spleen response at 6 months % decrease in spleen volume 0 | Al 8 Ss 6 3 -80 -100 12-H-0035, Hematology, NHLBI 15
Slide 16: Bone marrow response at months
Pretreatment At6 months Bone marrow response at 6 months % change in tumor burden 50 25 4 : Mh -100 — 12-H-0035, Hematology, NHLBI 16
Slide 17: Responses to ibrutinib appear durable
Responses to ibrutinib appear durable PFS probability 08 06 o4 02 0.0 a ‘| PDat 3 weeks presumed Richter’s PFS estimate at 12 months 94% Three events: transformation. Two deaths at day +3 and at 7 weeks. a 4 6 8 10 2 Months on Study 12-H-0035, Hematology, NHLBI 17
Slide 18: Ibrutinib inhibits tumor proliferation in the lymph node
Pre treatment At 2 months Ibrutinib inhibits tumor proliferation in the lymph node 5 £ 8 £ 2 a core biopsies 12-H-0035, Hematology, NHLBI 18
Slide 19: Ibrutinib inhibits BCR signaling in CLL cells in the lymph node
Ibrutinib inhibits BCR signaling in CLL cells in the lymph node €ccl4 Upregulation of BCR <EGRI Quantitative target genes in CLL = < KRG PCR i < cells in the lymph node. <€GFIt assay Herishanu, Blood 2011 Reduction in BCR target gene expression by ibrutinib (lymph node) 0 0 Relative gene 4 A express
Slide 20: Rapid and sustained decrease in BCR and NF-κB target genes in circulating CLL cells
Rapid and sustained decrease in BCR and NF- «B target genes in circulating CLL cells BCR target gene NF-«B target gene expression expression (in CD19+ purified cells) (in CD19+ purified cells) Relative expression onibrutinib / baseline (log2) Study day 12-H-0035, Hematology, NHLBI 20
Slide 21: Decrease in PLCy2 activation by ibrutinib confirms on-target effect in vivo
Decrease in PLCy2 activation by ibrutinib confirms on-target effect in vivo Phosphorylation of PLCy2 by flow cytometry of CLL cells in the blood 80 P<.001 —— %CLL 60 we cells pPLCy2 40 positive 20 0 Pre 12-H-0035, Hematology, NHLBI 21
Slide 22: Downregulation of cellular activation and proliferation by ibrutinib
Downregulation of cellular activation and proliferation by ibrutinib (CD69 on CLL cells in the blood) 60 % cD69 40 positive CLL cells 7° 0 Activation P<.001 —__ T- Pre Proliferation (Ki67 in CLL cells in the blood) 4 P< 001 % 3 Ki67 TT positive 2 CLL cells 4 ; | Pre Day 28 12-H-0035, Hematology, NHL
Slide 23: Summary and Conclusions
Summary and Conclusions Ibrutinib as a single agent is well tolerated and highly effective in CLL. — High response rates irrespective of 17p deletion. Responses appear durable. Rapid disease control in all anatomic sites. Rapid and sustained inhibition of BCR and NF-KB signaling in vivo confirm on t
Slide 24: Supported by the Intramural Research Program of NHLBI/NIH
Supported by the Intramural Research Program of NHLBI/NIH Our patients for participating Mohammed Farooqui Sarah Herman Georg Aue Nakhle Saba Janet Valdez Susan Soto Rashida Mustafa Jade Jones Andrew Lipsky Irina Maric Laboratory Medicine Stefania Pittaluga Diane Arthur Pathology Richard Cheng Franc